In a study of patients whose pulmonary arterial hypertension was associated with connective tissue disease (PAH-CTD), those patients who received riociguat showed an increase of 18 meters in their mean six-minute walking distance at week 12 compared with a decrease of 8 meters (about 26 feet.) in patients given placebo. In patients with the specific diagnosis of systemic sclerosis (PAH-SSc), the increase was smaller (4 meters), but the decrease was greater in the placebo group. These results suggest that riociguat “may prevent worsening of [the six-minute walking distance] in these patients,” the researchers stated.

Click here for more.